2023 World Conference on Lung Cancer (Posters)-P2.12. Cerebrospinal Fluid is an Alternative Medium of Liquid Biopsy for Patients with Brain Parenchymal Metastases from Non-Small Cell Lung Cancer

P2.12. Cerebrospinal Fluid is an Alternative Medium of Liquid Biopsy for Patients with Brain Parenchymal Metastases from Non-Small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

A study presented at WCLC 2023 investigated the use of cerebrospinal fluid (CSF) as a medium for liquid biopsy in patients with brain parenchymal metastases (BPM) from non-small cell lung cancer (NSCLC). The study aimed to determine the sensitivity of CSF in detecting mutations in these patients. CSF and plasma samples were collected from 18 NSCLC patients with BPM and subjected to gene panel sequencing. <br /><br />The results showed that 50% of the patients did not have any mutations detected in either CSF or plasma. The most commonly mutated genes were EGFR and TP53, while CSMD3, CDKN2A, CDK6, PRKDC, FGFR3, and SMARCA4 were exclusively detected in CSF. The average rates of shared mutations, exclusive CSF mutations, and exclusive plasma mutations were 28%, 37%, and 35%, respectively.<br /><br />Based on these findings, the study suggests that CSF may be a promising alternative source for liquid biopsy in patients with BPM. This could potentially provide valuable genetic information for targeted therapy in these patients. Keywords associated with this study include brain parenchymal metastases, cerebrospinal fluid, and plasma. The study falls under the track of metastatic non-small cell lung cancer-targeted therapy.

Asset Subtitle

Jianing Chen

Meta Tag

Speaker Jianing Chen

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

WCLC 2023

cerebrospinal fluid

liquid biopsy

brain parenchymal metastases

non-small cell lung cancer

CSF

gene panel sequencing

mutations

EGFR

TP53